

20th

Residential Course on Clinical Pharmacology of Antiretrovirals

29
31³⁰
JANUARY
2025

Residential and
online courses

WEDNESDAY 29 JAN

3:00 PM - 6:30 PM

THURSDAY 30 JAN

9:00 AM - 5:30 PM

FRIDAY 31 JAN

9:00 AM - 1:30 PM

www.fcavturin.it





Organizing Secretariat and CME Provider



CONTACT

Phone: **+39 011 0267950**

Fax: **+39 011 0267954**

E-mail: **segreteria@hdcons.it**

Web: **www.hdcons.it**

COURSE RATIONALE

The course is a remarkable platform for learning, networking, and advancing the understanding of clinical pharmacology in the context of viral, bacterial and fungal infections. It presents a unique opportunity for interdisciplinary cross-fertilization of ideas and incorporation of new approaches in all areas of anti-infective agents, from target identification to clinical application.

Combined as in-person and virtual participation to ensure a wide-reaching and inclusive engagement, the course brings together experts from different fields. Now in its 20th edition, it has progressively expanded to encompass a broad range of topics of clinical pharmacology, thus allowing every participant to exchange the latest scientific knowledge and engage in a comprehensive educational experience.

Not only designed for clinicians who wish to deepen their knowledge about PK/PD aspects of HIV research and medicine, the 3-day course is also a focus on novel issues covering proper use of antibiotics and antifungal agents. Monoclonal antibodies prophylaxis and up-to-date treatment approaches for patients with HIV, RSV and COVID will be also explored. Additionally, pharmacological principles and clinical practical competence in the areas of long-acting anti-infective agents will be widely analyzed and discussed.

COURSE DIRECTOR

G. Di Perri

SCIENTIFIC SECRETARIAT

S. Bonora, A. Calcagno

Phone: + 39 011 4393980/4393867, Fax: +39 011 4393882

E-mail: stefano.bonora@unito.it - andrea.calcagno@unito.it



FACULTY

Massimo Andreoni, Department of Infectious Diseases, University “Tor Vergata”, Rome, Italy.

Michele Bartoletti, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Infectious Disease Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Marta Boffito, Department of Sexual Health & HIV, Chelsea & Westminster NHS Trust, London, UK.

Stefano Bonora, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.

Andrea Calcagno, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.

Antonella Castagna, Infectious Diseases, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy.

Dario Cattaneo, Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

Marta Clokie, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.

Silvia Corcione, Department of Medical Science, University of Turin, AOU Città della Salute e della Scienza di Torino, Italy..

Davide Corti, Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Jessica Cusato, Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Italy.

Alessandra D’Abramo, Department of Infectious Diseases, IRCCS “Lazzaro Spallanzani”, Rome, Italy.

Antonio D’Avolio, Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Italy.

Francesco Giuseppe De Rosa, Department of Medical Science, University of Turin, AOU Città della Salute e della Scienza di Torino, Italy.

Giovanni Di Perri, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.

Susanna Esposito, Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University of Parma, Italy.

Marco Falcone, Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Italy.

Micol Ferrara, Infectious Diseases, Department of Medical Sciences, University of Torino, Italy.

Courtney V. Fletcher, Antiviral Pharmacology Laboratory, UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Emanuele Focà, Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.

Massimo Galli, Department of Infectious Diseases, University of Milan, Italy.

Rodolphe Garraffo, Pharmacology Laboratory, CHU Pasteur, Nice, France.

Valeria Ghisetti, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.

Sara Gianella Weibel, Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA.

Andrea Gori, Infectious Diseases Unit, ASST Fatebenefratelli, Ospedale L. Sacco, Milan, Italy; Infectious Diseases Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Italy.

Saye Khoo, Department of Pharmacology and Therapeutics, University of Liverpool, UK.

Loreta Kondili, Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.

Pietro Lampertico, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Italy.

Scott L. Letendre, Department of Infectious Diseases, University of California San Diego School of Medicine, La Jolla, CA, USA.

Catia Marzolini, Service of Clinical Pharmacology, University Hospital Lausanne, Lausanne and Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.

Cristina Mussini, Institute of Infectious Diseases, University of Modena, Italy.

Giuseppe Nunnari, Institute of Infectious Diseases, University of Messina, Italy.

Andrew Owen, Department of Pharmacology and Therapeutics, Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK.

Carlo Federico Perno, Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy.

Francesco Scaglione, Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy - Department of Laboratory Medicine, Niguarda Metropolitan Hospital, Milan, Italy

Mattia Trunfio, University of California San Diego School of Medicine and Sanford Stem Cell Institute, La Jolla, CA, USA.

Updated information will
be found on the
course website:
www.fcavturin.it

LANGUAGE

The official language of the
Course is English.
There is no simultaneous
interpretation.

PROGRAMME

WEDNESDAY, **29 JAN 2025**
AFTERNOON SESSION

1st WEBINAR

- 15:00 Course registration
- 15:30 Welcome and introduction to the Course
G. Di Perri, S. Bonora, A. Calcagno
- 15:40 Special Guest Lecture: Design and development of Monoclonal Antibodies for Infectious Diseases (**D. Corti – introduced by G. Di Perri**)

SESSION I - NEW STRATEGIES FOR TREATMENT AND PREVENTION OF INFECTIOUS DISEASES

Chair: **S. Bonora, A. Calcagno**

- 16:10 Advancing bacteriophages as a treatment of antibiotic-resistant bacterial infections (**M. Clokie**)
- 16:30 Prevention and treatment of Respiratory Syncytial Virus (**S. Esposito**)
- 16:50 Plenary discussion
- 17:10 [Coffee break](#)
- 17:30 Complicated COVID-19: who is at risk in 2025? (**A. D'Abramo**)
- 17:50 New Monoclonal Antibodies for prevention and treatment of COVID-19 (**G. Di Perri**)
- 18:10 Plenary discussion
- 18:30 Closing remarks day1

SESSION III - TDM: MEASURING THE DRUGS IN CLINICAL PRACTICE

Chair: A. D'Avolio, R. Garraffo, E. Focà

- 9:00 Keynote lecture: Do we need TDM of long-acting antiretroviral agents? **(C. Marzolini)**
- 9:20 Is it still worth to measure oral anti-HIV drugs in 2025? **(M. Ferrara)**
- 9:40 TDM of antifungals agents: triazoles and beyond **(S. Corcione)**
- 10:00 Antimicrobial TDM in critically ill adult patients **(M. Bartoletti)**
- 10:20 TDM of long-acting antibiotics **(D. Cattaneo)**
- 10:40 Plenary discussion
- 11:10 **Coffee break**

SESSION IV - CLINICAL PHARMACOLOGY AT THE BEDSIDE

Chair: A. Gori, G. Di Perri

- 11:30 Do we need pharmacogenomics for adequately using anti-infectives agents? **(J. Cusato)**
- 11:50 Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy of intrabdominal infections **(M. Falcone)**
- 12:10 The paradigm shifts of dosing rifampicin and other antimycobacterial drugs **(A. Calcagno)**
- 12:30 A clinic-pharmacological update on-lactamase inhibitor development **(F.G. De Rosa)**
- 12:50 Plenary discussion
- 13:15 **Lunch**

SESSION V - VIRAL HEPATITIS


Chair: **G. Di Perri, L. Kondili**

- 14:30 Update on Hepatitis Delta treatment with Bulevirtide (**P. Lampertico**)
- 14:50 HDV screening and care indications in HBsAg-positive patients (**L. Kondili**)
- 15:10 Plenary discussion

SESSION VI - LONG ACTING AND EXTENDED DELIVERY REGIMENS

Chair: **M. Andreoni, C. Mussini**

- 15:30 Challenges and opportunities of Long-Acting anti-HIV treatment (**A. Castagna**)
- 15:50 Perspectives on use of Long-Acting agents for treatment and prevention of HIV infection (**M. Boffito**)
- 16:10 Advancing the use of Long-Acting antimicrobial and antifungal treatments (**F. Scaglione**)
- 16:30 Innovative drug delivery systems for treatment and prophylaxis of infectious disease (**A. Owen**)
- 16:50 Plenary discussion
- 17:30 Closing remarks day 2



SESSION VII - LONG TERM THERAPEUTIC SUCCESS OF ANTI-HIV REGIMENS

Chair: **M. Galli, C.F. Perno**

- 9:00 Pharmacological determinants of long-term therapeutic success of anti-HIV regimens (**S. Bonora**)
- 9:20 Pipeline of oral antiretroviral regimens (**S. Khoo**)
- 9:40 Clinical pharmacology of old and new treatment schedules (**G. Di Perri**)
- 10:00 CNS effects of HAART in 2025 (**A. Calcagno**)
- 10:20 Plenary discussion
- 10:50 [Coffee break](#)

SESSION VIII - CHALLENGING THE HIV RESERVOIR

Chair: **G. Nunnari, V. Ghisetti**

- 11:10 Keynote lecture: The long-term neurocognitive decline in PLWH: which lessons learned (**S. Letendre**)
- 11:30 Suppressing asymptomatic CMV with letermovir reshapes cardiometabolic proteome in treated HIV (**S. Gianella Weibel**)
- 11:50 Tissue pharmacology of antiretrovirals: which role for HIV treatment and cure? (**C. Fletcher**)
- 12:10 CART cell therapy in HIV cure (**M. Trunfio**)
- 12:30 Plenary discussion
- 13:00 Closing remarks day 3 and CME questionnaire

TARGET AUDIENCE

The course is designed for healthcare professionals who are actively involved in the medical care of people with viral, bacterial and fungal infections.

CME credits will only be awarded to Italian participants who attend the entire course. These categories of health professionals are eligible for CME credit assignment: Physicians, Hospital Pharmacists, Biologists, Chemists and Lab Technicians.

CME Webinar

1

WEDNESDAY, **29 JAN 2025**

h. 3:30 PM - 6:30 PM

CME Code: **546-435790**

3 CME credits upon completion of the questionnaire after attending the live webinar

2

THURSDAY, **30 JAN 2025**

h. 9:00 AM - 1:15 PM

CME Code: **546-435796**

4,5 CME credits upon completion of the questionnaire after attending the live webinar

3

THURSDAY, **30 JAN 2025**

h. 2:30 PM - 5:30 PM

CME Code: **546-435801**

4,5 CME credits upon completion of the questionnaire after attending the live webinar

4

FRIDAY, **31 JAN 2025**

h. 9:00 AM - 1:00 PM

CME Code: **546-435802**

4,5 CME credits upon completion of the questionnaire after attending the live webinar

HOW TO ATTEND THE WEBINARS

The day before the start of the Course, an email will be sent to subscribers containing links and access credentials valid for all 4 modules.

The CME test must be completed within three days after the course has finished. At the end of the course it will be possible to download the certificate of participation from the online platform.

CME Residential

CME Code: **546-435778**

This congress is accredited with **13 CME credits** credits upon completion of the questionnaire after having attended all 3 days conference

REGISTRATION

Registration available on www.fcarvturin.it

Registration is mandatory in order to attend the residential course

Onsite registration includes:

- Admission to all course sessions
- Name tag
- Satchel
- Block notes and pen
- Free onsite wireless
- Coffee breaks and lunches indicated in the program

RESIDENTIAL COURSE LOCATION

All sessions will be held at the

Starhotels Majestic

Corso Vittorio Emanuele II 54, Turin

Phone: +39 011 539153

Fax: +39 011 534963



With the non-conditioning contribution of:

DIAMOND SPONSOR



SILVER SPONSORS



www.fcarvturin.it

Organizing Secretariat and CME Provider



CONTACT

Phone: +39 011 0267950

E-mail: segreteria@hdcons.it Web: www.hdcons.it